NCT05654506 - Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 17, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions

Proliferative Glomerulonephritis With Monoclonal IgG Deposits

Interventions

DRUG

Daratumumab

1800 mg subcutaneous (SC) injection (total amount 15 mL) into the right/left abdominal area once weekly for 8 doses followed by once every 2 weeks for an additional 8 doses

Trial Locations (4)

27599

RECRUITING

University North Carolina at Chapel Hill, Chapel Hill

32224

RECRUITING

Mayo Clinic, Jacksonville

55905

RECRUITING

Mayo Clinic, Rochester

97239

NOT_YET_RECRUITING

Oregon Health and Science University, Portland